Signaling pathway ‘key needle within the haystack’ driving Barrett’s, esophageal cancer
Healio: Kishore Guda, associate professor at the School of Medicine, discussed a new study focused on a signaling pathway involved in the development of Barrett’s esophagus and esophageal adenocarcinoma. “The widely known immune checkpoint therapies have also proven not effective for the vast majority of these cancers and solid tumors in general,” Guda said. “We are, therefore, currently developing a novel immune cell-based therapy to specifically target these cancers expressing EphB2.”